Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Nitrosamine Risk Assessment in Drug Products: Common Gaps and Regulatory Expectations

 

Across the pharmaceutical industry, nitrosamine control has shifted from a niche impurity topic to a global regulatory priority. What once felt like a specialized concern is now a full expectation: every drug product must undergo a structured, defensible, and complete risk assessment for potential nitrosamine impurities.

Despite clear guidance from FDA, EMA, Health Canada, and Swissmedic, companies still submit assessments that are incomplete, vague, or missing critical product information. As a result, regulators quickly identify a gap: the assessment relies on general assumptions, not real product-specific knowledge.

Therefore, this article explains why drug-product nitrosamine assessments fail, what regulators expect, and what information is missing in most submissions.

Challenges Faced

A detailed GAP analysis in Quality Management Systems is essential for identifying process deficiencies effectively.
  • Industry Blind Spot: Treating Assessments as Formalities:

    Many treat nitrosamine assessments as routine paperwork, underestimating product-specific detail. Incomplete or copied data reduces traceability and regulatory confidence, often resulting in FDA 483s and EMA inquiries.

  • Regulatory Scrutiny: The client’s computerized system was under FDA inspection. Therefore, any gaps in validation documentation could result in findings or penalties.
  • Document Volume Complexity: Validation documentation included plans, protocols, scripts, reports, and traceability matrices. Therefore, maintaining consistency across all documents became complex.
  • Time Sensitivity: The GAP assessment had to be completed within a short timeframe. As a result, internal regulatory deadlines increased pressure on execution.

Zamann Pharma Support’s Approach

  • Project Initialization: An initial kick-off meeting was conducted with all related areas. This step defined goals, timelines, and concerns. The validation lifecycle was reviewed to map the GAP assessment scope.
  • Document Review: Each validation document was analyzed against FDA regulations and GAMP guidelines. The review included URS, FS, VMP, IQ, OQ, PQ, traceability matrices, and change control records.
  • Key Topic Evaluation: Risk assessments were compared with GAMP risk-based principles. In addition, testing protocols were checked against FDA data integrity expectations, including audit trails and electronic signatures (21 CFR Part 11).
  • Structured Findings: Findings were grouped into three levels based on regulatory impact. Critical GAPs were direct non-conformances with FDA or GAMP5 requirements. Major GAPs indicated potential regulatory observations. In addition, Minor GAPs were documentation improvements without immediate compliance risk.
  • CAPA Proposal: CAPAs were defined for each GAP. Therefore, URS and FS were revised for better alignment. In addition, test protocols were updated for audit trails and e-signatures. Traceability matrices were improved for full requirement coverage. Moreover, training was introduced for validation principles. Finally, document templates were updated for audit readiness and consistency.
  • Implementation Support: Templates and examples were provided. Workshops were conducted with the client team. A follow-up system was established to track CAPA execution.

Results Achieved

  • Regulatory Compliance Alignment: The GAP assessment and CAPAs aligned validation documentation with FDA and GAMP5 requirements, ensuring a compliant state.
  • Improved Documentation Structure: Documentation was streamlined and reorganized, making it easier to manage, review, and present during inspections.
  • Risk Mitigation: Critical GAPs were identified and addressed, reducing regulatory findings risk and lowering compliance exposure.
  • Team Empowerment: Workshops and CAPA involvement improved the team’s understanding of validation principles and documentation expectations.
  • Timely Completion: The GAP assessment and remediation plan were completed on time, enabling regulatory submission deadlines to be met.
Laboratory
Pharmaceutical quality team reviewing nitrosamines risk assessment documentation aligned with ICH M7 and current regulatory compliance requirements
Services

Nitrosamines Regulatory Compliance

We assist pharmaceutical teams in assessing and managing nitrosamines risks by aligning processes with ICH M7 requirements and current regulatory expectations.

Read More

Contact Us

Need help? Don't hesitate to get in touch
Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

FAQ

1. Why are nitrosamine drug-product risk assessments rejected?

Assessments are rejected when they are not product-specific and rely on generic templates. Regulators identify missing linkage to controlled manufacturing and formulation data. EMA and FDA require evidence-based justification tied to actual production conditions.

2. What is the most critical data gap in nitrosamine risk assessments?

The main gap is missing material-level traceability for excipients, APIs, and packaging components. Assessments often lack supplier-specific data and verified MMR/MPR alignment. This prevents proper evaluation of nitrosamine formation risk pathways.

3. What makes a nitrosamine assessment inspection-ready?

An inspection-ready assessment is fully traceable to controlled documents and updated after any process or supplier change. It includes complete formulation, process, and material data without assumptions. Regulators expect continuous lifecycle maintenance of the assessment.